Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006);Actividad comparativa de daptomicina frente a microorganismos grampositivos: Programa SENTRY España (2002-2006)

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue 8, 2008, Pages 489-494

  Loza, Elena ^a   Morosini, María Isabel ^a   Pascual, Álvaro ^b   Tubau, Fe ^c   Alcalá, Juan ^b   Liñares, Josefina ^c   Hernández Bello, José Ramón ^b   Baquero, Fernando ^a   Perea, Evelio ^b   Martín, Rogelio ^c   Jones, Ronald N ^d   Cantón, Rafael ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d JMI LABORATORIES   (United States)

Author keywords

Daptomycin; Gram positive; In vitro activity; Lipopeptides; Resistance surveillance

Indexed keywords

AMPICILLIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; METICILLIN; PENICILLIN DERIVATIVE; TEICOPLANIN; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; BROTH DILUTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMPARATIVE STUDY; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SPAIN; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PYOGENES;

EID: 56249109066     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13127453     Document Type: Article

References (33)

1. Eliopoulos GM, Willey S, Reiszner E, Spitzer PG, Caputo G, Moellering RC Jr. In vitro and in vivo activity of LY 146032, a new cyclic lipoptide antibiotic. Antimicrob Agents Chemother. 1986;30:532-5.
2. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother. 2000;44:1062-6.
3. Piper KE, Steckelberg JM, Patel R. In vitro activity of daptomycin against clinical isolates of Gram-positive bacteria. J Infect Chemother. 2005;11:207-9.
4. Diederen BM, Van Duijn I, Willemse P, Kluytmans JA. In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains. Antimicrob Agents Chemother. 2006;50:3189-91.
5. Pfaller MA, Sader HS, Jones RN. Evaluation of the in vitro activity of daptomycin against 19,615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). Diagn Microbiol Infect Dis. 2007;57:459-65.
6. Rybak MJ. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Clin Microbiol Infect. 2006;12 Supl 1:24-32.
7. Andrew JH, Wale MC, Wale LJ, Greenwood D. The effect of cultural conditions on the activity of LY146032 against staphylococci and streptococci. J Antimicrob Chemother. 1987;20:213-21.
8. Lamp KC, Rybak MJ, Bailey EM, Kaatz GW. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob Agents Chemother. 1992;36:2709-14.
9. Clinical and Laboratory Standards Institute/NCCLS. 2006. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. CLSI/NCCLS M100-S16. Clinical and Laboratory Standards Institute, Wayne, Pa.
10. Hancock RE. Mechanisms of action of newer antibiotics for Gram-positive pathogens. Lancet Infect Dis. 2005;5:209-18.
11. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:1079-82.
12. Sader HS, Fritsche TR, Jones RN. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob Agents Chemother. 2006;50:2330-6.
13. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC Jr, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother. 2006;50:1581-5.
14. Silverman JA, Oliver N, Andrew T, Li T. Resistance studies with daptomycin. Antimicrob Agents Chemother. 2001;45:1799-802.
15. Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2005;43:5285-7.
16. Vikram HR, Havill NL, Koeth LM, Boyce JM. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol. 2005;43:5384-7.
17. Long JK, Choueiri TK, Hall GS, Avery RK, Sekeres MA. Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin Proc. 2005;80:1215-6.
18. Fraher MH, Corcoran GD, Creagh S, Feeney E. Daptomycin-resistant Enteroccoccus faecium in a patient with no prior exposure to daptomycin. J Hosp Infect. 2007;65:376-8.
19. Martone WJ, Lamp KC. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry. Curr Med Res Opin. 2006;22:2337-43.
20. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653-65.
21. Cunha BA, Eisenstein LE, Hamid NS. Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: Cure with prolonged/high-dose daptomycin without toxicity. Heart Lung. 2006;35:207-11.
22. Fluit AC, Wielders CL, Verhoef J, Schmitz FJ. Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J Clin Microbiol. 2001;39:3727-32.
23. Johnson AP. Antibiotic resistance among clinically important Gram-positive bacteria in the UK. J Hosp Infect. 1998;40:17-26.
24. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003;348:1342-7.
25. Johnson P, Mushtaq S, Warner M, Livermore DM. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid. Int J Antimicrob Agents. 2004;24:315-9.
26. Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2007;58:163-70. Epub 2007 Mar 26.
27. Fluit AC, Schmitz FJ, Verhoef J, Milatovic D. In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants. Antimicrob Agents Chemother. 2004;48:1007-11.
28. Patel JB, Jevitt LA, Hageman J, McDonald LC, Tenover FC. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis. 2006;42:1652-3.
29. Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol. 2006;44:655-6.
30. Lewis JS II, Owens A, Cadena J, Sabol K, Patterson JE, Jorgensen JH. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother. 2005;49:1664-5.
31. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother. 2005;55:283-8.
32. Stefani S, D'Amico G, Mezzatesta ML, Lo Tauro R, Pellegrino MB, Nicoletti G. High-level resistance to aminoglycosides in enterococci; incidence and alternative active antibiotic combinations in vitro. Drugs Exp Clin Res. 1990;16:391-5.
33. Streit JM, Steenbergen JN, Thorne GM, Alder J, Jones RN. Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis. J Antimicrob Chemother. 2005;55:574-8.